Explore the latest in pharmacoeconomics from The JAMA Network, including cost-effectiveness evaluations, value-based pricing, coverage and access, and more.
This Viewpoint cites instances of how the availability of lifesaving cancer drugs in sub-Saharan Africa are increasing overall survival to argue for the increased dissemination of cost-effective or free cancer drugs.
This study examines PCSK9i cost-sharing requirements for Medicare Part D plans nationwide, which insure 41 million beneficiaries.
This study evaluates the cost-effectiveness of evolocumab in patients with atherosclerotic cardiovascular disease when added to standard background therapy.
This Viewpoint describes the Priority Antimicrobial Value and Entry (PAVE) award, which has been proposed to address the problem of antimicrobial-resistant infections using limited public funds to shift to value-based payment for new, high-priority antimicrobial drugs.
This Viewpoint uses FDA approval of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) agent approved for human use, to discuss escalating drug prices for oncology therapies and the complex considerations of outcomes and value that should justify the pricing.
This Special Communication reviews the peer-reviewed medical and health policy literature to identify studies that described the different types of patent protection and regulatory exclusivities that shield brand-name prescription drugs from competition and help to sustain high drug prices.
This study traces the use of the anticancer drug capecitabine through its loss of patent protection to evaluate the effect of generic pricing on the cost of oral anticancer drugs.
This analysis of US Securities and Exchange Commission filings provides a contemporary estimate of research and development spending to develop 10 new cancer drugs.
This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.
This Viewpoint discusses a New York law that allows the state to negotiate rebates with manufacturers to obtain value-based prices for drugs in its Medicaid program and assesses the potential effects of value-based pricing.
This observational study compares the prices of minoxidil products for men and women at retail pharmacies.
This cost analysis assesses Medicare and patient out-of-pocket costs for topical steroids and models potential savings that could result from substitution of the least expensive topical steroid from the corresponding potency class.
This special communication examines the role of prescription drug rebates in driving up Medicare Part D expenditures and consumer out-of-pocket costs.
This Viewpoint identifies stakeholders in the financing and distribution of pharmaceuticals in the United States and describes their flow from manufacturers through distributors, managers, and retailers to patients.
This Viewpoint explores why biosimilars for chronic diseases, the largest category of biological therapies, are unlikely to yield cost savings.
This study examines coverage and cost-sharing for chronic obstructive pulmonary disease inhalers in Medicare Part D plans.
This study examines 5-year trends in Medicare data and compares prices for older cancer drugs with prices for newer cancer drugs.